番茄社区app

Combination associated with favorable R0 resection and survival rates

Almost 50% improvement in median survival, but against a suboptimal control regimen

No event-free survival benefit with atezolizumab versus placebo in phase III trial

Strength of association increased in more recent birth cohorts

The drug had favorable safety compared with first-generation PARP inhibitors in phase I/II study

ORR of 71% that deepened over time and favorable safety profile with linvoseltamab

Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all

Only 43% showed clinical benefit within 5 years

Clear decline for cervical cancer, awareness of other cancers remains stagnant

Fewer actionable mutations, less likely to meet genomic criteria for immunotherapy

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

Moreover, a significant proportion do not qualify for genetic screening under current guidelines

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

Overall response rate of 90% in patients who received highest doses of REGN5459